Aktienanalyse zu Phathom Pharmaceuticals Inc (PHAT)PHATPhathom Pharmaceuticals Inc

Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of novel treatments for gastrointestinal diseases. It has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) for the United States (U.S.), Europe and Canada. PCABs are a novel class of molecules that block acid secretion in the stomach. The Company markets vonoprazan in the U.S. as VOQUEZNA (vonoprazan) tablets for the relief of heartburn associated with non-erosive gastroesophageal reflux disease (Non-Erosive GERD) in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of VOQUEZNA DUAL PAK (vonoprazan tablets, amoxicillin capsules) and VOQUEZNA TRIPLE PAK (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) for the treatment of H. pylori infection in adults. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Phathom Pharmaceuticals is a good buy right now due to its recent strong revenue growth, reporting $74.3 million in Q2 2026, an 88% year-over-year increase, and achieving its first operating profit of $1.6 million excluding stock-based compensation. However, the company has lowered its 2026 revenue guidance to $310-325 million, which is a significant risk. The current price of $9.18 is well below analyst targets, suggesting potential upside.